BofA Finance LLC has recently filed a pricing supplement for $484,000 in callable yield notes, fully guaranteed by Bank of America Corporation. This significant move highlights BofA Finance's ongoing strategy to enhance its financial product offerings in the competitive landscape of national commercial banking.
The callable yield notes are linked to the performance of major stock indices, including the Dow Jones Industrial Average, the Russell 2000, and the S&P 500. Investors will receive contingent income based on the performance of these indices, which could attract a range of investors looking for innovative investment opportunities.
Background
BofA Finance LLC, classified under the SIC code 6021 for National Commercial Banks, is a subsidiary of Bank of America Corporation. The company is incorporated in Delaware and operates out of Charlotte, North Carolina. Its recent filings include multiple pricing supplements, all dated November 4, 2026, indicating an active approach to capital management and product development.
What the Filing Says
The filing states that the notes are due on November 8, 2029, and will be issued on November 6, 2026. The contingent coupon rate is set at 8.50% per annum, payable monthly, contingent on the performance of the underlying indices. The filing emphasizes that payments on the notes are subject to the credit risk of BofA Finance LLC and Bank of America Corporation, the guarantor of the notes.
Impact
This financial product may affect a variety of stakeholders, including investors seeking higher yields and other banks looking to compete in the structured product market. The notes' structure, which incorporates performance-based payments, could influence how similar products are designed across the industry.
What's Next
The filing does not specify what happens next, but the issuance of the notes is expected to proceed as planned, with potential investor interest shaping future offerings.
Read Next
Andersen Aggregator files new offering for internal reorganization
HSBC USA Inc. Files Pricing Supplement for New Notes
Mkango Rare Earths files prospectus for merger with CPTK
Evommune files prospectus supplement for capital update
Yum Brands officer Erika Burkhardt files to sell shares
Matsuda Masaru to Sell 40,000 Shares of Arcutis Biotherapeutics




